Quentir Medicine Monitor
Evidence-based insights for quantum medicine. Published by Quentir Systems LLC · November 7, 2026.
A team from the Shanghai photonics company TuringQ and Shanghai Jiao Tong University has published a protein design model whose training borrows a photonic quantum circuit as a helper, and has taken the proteins it generated into the laboratory. The preprint, posted to arXiv on 5 November 2026, reports antifungal activity for three designed plant defensins and measured enzyme activity for designed xylanases and short-chain dehydrogenases.
The quantum component sits in one specific place: the training loop. A photonic quantum neural network, or a quantum version of a Kolmogorov-Arnold network, serves as an auxiliary head that predicts how soluble a sequence will be, and its prediction error helps shape the shared representation the design model learns from. Once training finishes, every sequence is generated by an ordinary classical process on ordinary computers.
The author list spans a company and a university physics department. Ke-Xin Tang, Zhen-Qiang Weng, Kai Yan, Yao-Yao Lu, Yu-Ze Zhu, Jun-Jie He, Jie-Cheng Yang, Xiang Zhao and Lin Yang are at TuringQ; Hang Song and Xian-Min Jin are at the School of Physics and Astronomy and the State Key Laboratory of Photonics and Communications at Shanghai Jiao Tong University, with further affiliations at the Chip Hub for Integrated Photonics Xplore in Wuxi, Atomology Co. and Hefei National Laboratory. The work is funded by the National Key R&D Program of China and the national Innovation Program for Quantum Science and Technology.
What DiffSequence-Q generates, and how a secondary-structure target and a solubility target enter one model
Protein design asks for an amino-acid sequence that folds the required way and survives contact with water and with a production host. The model the team calls DiffSequence-Q starts from a noisy sequence and repeatedly replaces amino acids until a clean sequence remains, a procedure known as multinomial diffusion. Two conditions ride along at every step: the required secondary structure for each individual residue, written in the nine-state DSSP vocabulary, and a single continuous number for the solubility the designer wants.
Solubility is where the quantum part enters. During joint training, a small auxiliary head reads the shared Transformer representation of a sequence and predicts a solubility score, and the error in that prediction is optimized together with the design objective. In the classical reference version the head is a multilayer perceptron. In the two quantum versions it is a photonic quantum neural network, whose optical modes carry the computation, or a quantum Kolmogorov-Arnold network, which replaces fixed network weights with learnable one-variable functions built from a Fourier series of a chosen order.
On the standard CATH v4.2 test split introduced by Ingraham and colleagues in 2019, the pretrained design model gave the highest secondary-structure recovery of the four models compared when the whole sequence is regenerated, ahead of the strongest baseline by 8.96 percentage points on the strict nine-state measure and 4.77 percentage points on the coarse three-state measure. Its three-state recovery was 60.57 percent with the whole sequence masked, 66.61 percent with the first half masked and 63.11 percent with the last half masked. The authors also report that one of the baselines, the multimodal protein language model DPLM-2, produced structures with the highest mean confidence score in all three settings, so the ranking depends on which quality is measured.
Quantum pillar: computing. Technology readiness: TRL 4 of 9. The designed proteins were produced in bacteria and assayed on the laboratory bench, with no animal or human study, and the photonic hardware carried only a short training demonstration.
Where TuringQ's Gen3 photonic computer actually ran: ten training epochs, with simulation behind every solubility comparison
The preprint, which has not yet been peer reviewed, separates its two kinds of quantum results, and a reader should keep them apart. All the solubility comparisons between heads come from numerical simulation of the photonic circuits, and all of them redesign a single reference protein: human monoamine oxidase, UniProt P21397, 527 residues long, with 179 positions rewritten by the model and the other 348 held at their reference amino acids. That benchmark is separate from the five design tasks whose products went to the bench. For the quantum neural network the mean predicted solubility rose from 0.4736 with two optical modes to 0.6941 with thirty-two, which is 14.0 percent above the classical reference value of 0.6088, and then fell back to 0.6315 with sixty-four modes. For the Kolmogorov-Arnold version the highest mean score, 0.7471, or 22.7 percent above the same reference, came at Fourier order six, while orders one and two scored 0.4623 and 0.4449, below the classical head. Each configuration was judged on 100 such redesigned monoamine oxidase sequences, and the authors state plainly that the trend is not monotonic, so a larger quantum head does not reliably give a better result.
These scores are predictions, not measurements. They come from a separate solubility predictor the team trained on the cleaned Escherichia coli solubility dataset of DeepSol, published by Khurana and colleagues in Bioinformatics in 2018, which retains 66,940 sequences with experimental soluble-or-not labels. A hospital pharmacy or a process chemist would call this an in-silico score for a property that is settled at the fermenter.
Physical hardware appears in one further experiment. The team implemented a Clements interferometer mesh on TuringQ's Gen3 photonic quantum computer, took expectation values directly from the device on a subset of the training data, and obtained gradients through the parameter-shift rule. Over the first ten training epochs the total loss fell from 0.4508 to 0.2407 and the solubility loss from 0.4179 to 0.2272. The Kolmogorov-Arnold run used a differentiable response map calibrated from photon-detection probabilities measured earlier, with that calibration held fixed, and its total loss fell from 0.7927 to 0.6788. The authors write that neither experiment should be read as a hardware implementation of the simulated comparisons. Photonic processors have been proposed for this part of pharmaceutical research before, as in the agreement the Korea Research Institute of Bioscience and Biotechnology signed with Quandela in Paris in September 2026, and the distance between a training-loop demonstration and a production design run is the thing to measure in each case.
What the assays measured: inhibition zones of about 10 to 13 millimeters against Aspergillus niger, xylanases at 1.92 to 2.21 units per milligram
The team generated 1,000 candidate sequences for each of five protein systems: a plant defensin of 50 residues, a xylanase of 185, a short-chain dehydrogenase of 262, a transaminase of 473 and the UDP glycosyltransferase UGT76G1 of 458, each anchored to a deposited structure such as Protein Data Bank entry 1BK8 for the defensin. Candidates were ranked by sequence identity to the reference, secondary-structure similarity, predicted solubility and the conservation of key motifs in alignments, and a small number went forward to the bench.
Three defensin constructs were expressed in E. coli BL21(DE3) as tandem pairs joined by a flexible linker with a histidine tag, then applied to agar plates inoculated with the mold Aspergillus niger. After incubation at 28 degrees Celsius the plates showed growth-free zones of roughly 10 millimeters for the first construct, 12 to 13 millimeters for the second and 10 millimeters at the earlier time points for the third, each assay in triplicate. Four designed xylanases gave specific activities between 1.92 and 2.21 units per milligram in the standard reducing-sugar assay and kept full activity after two hours at 55 degrees Celsius. Two short-chain dehydrogenases reached 55.25 and 53.10 units per milligram.
What the activity means for medicine needs stating carefully. Defensins are small antimicrobial peptides that plants and animals use as a first line of defense, and interest in them as anti-infective leads is long-standing, but an inhibition zone on a plate of mold is a biochemical result and not a therapeutic one. The xylanases and dehydrogenases belong to industrial and biocatalytic chemistry rather than to the clinic. The authors name quantitative yields of soluble protein, fold stability and structural characterization as the work still to do.
How Quentir reads the TuringQ paper: four questions before a discovery group pays for quantum-assisted protein design
The paper is unusually honest about its own boundaries, which makes it useful as a template for questions. A research director offered quantum-assisted protein design can ask four things. Which reported numbers came from a quantum device, and which from a simulation of one? Was the improved property measured in a laboratory or predicted by another model? Counting parameters, did the quantum head beat a classical head of comparable size under identical generation conditions, and does the improvement grow smoothly with the size of the quantum circuit? Were the designed molecules taken into a biological assay, and in which organism?
For arXiv 2611.08434 the answers are: a ten-epoch training run on the Gen3 photonic computer, with simulation behind the headline percentages; predicted by a model trained on 66,940 labeled sequences; the quantum heads carried 22,592 parameters for the thirty-two-mode network and 19,545 at Fourier order six against 18,649 for the classical head, on a curve that rises and falls; and yes, in E. coli expression and plate and enzyme assays for three protein families. A design pipeline that produces active defensins and thermostable xylanases could matter commercially whatever its training head is made of, once yields, competing methods and demand are assessed. The open question the preprint leaves is whether the photonic head contributes anything a well-sized classical head could not, and the authors' nonmonotonic curves are the reason that question stays open.
Sources
Primary source: the arXiv preprint by Ke-Xin Tang, Zhen-Qiang Weng, Kai Yan, Yao-Yao Lu, Yu-Ze Zhu, Hang Song, Jun-Jie He, Jie-Cheng Yang, Xiang Zhao, Lin Yang and Xian-Min Jin of 5 November 2026. Also drawn on: the DeepSol solubility paper by Khurana and colleagues, the CATH design benchmark of Ingraham and colleagues, the Protein Data Bank entry for the reference plant defensin, and earlier Quentir coverage.